BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sistigu A, Manic G, Obrist F, Vitale I. Trial watch - inhibiting PARP enzymes for anticancer therapy. Mol Cell Oncol 2016;3:e1053594. [PMID: 27308587 DOI: 10.1080/23723556.2015.1053594] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 David R, Gee S, Khan K, Wilson A, Doherty A. Three dimensional and microphysiological bone marrow models detect in vivo positive compounds. Sci Rep 2021;11:21959. [PMID: 34754012 DOI: 10.1038/s41598-021-01400-5] [Reference Citation Analysis]
2 Kobayashi M, Ishizaki Y, Owaki M, Matsumoto Y, Kakiyama Y, Hoshino S, Tagawa R, Sudo Y, Okita N, Akimoto K, Higami Y. Nutlin-3a suppresses poly (ADP-ribose) polymerase 1 by mechanisms different from conventional PARP1 suppressors in a human breast cancer cell line. Oncotarget 2020;11:1653-65. [PMID: 32405340 DOI: 10.18632/oncotarget.27581] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Suraweera A, O'Byrne KJ, Richard DJ. Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi. Front Oncol 2018;8:92. [PMID: 29651407 DOI: 10.3389/fonc.2018.00092] [Cited by in Crossref: 288] [Cited by in F6Publishing: 251] [Article Influence: 72.0] [Reference Citation Analysis]
4 Dong X, Yang L, Wang H. miR-520 promotes DNA-damage-induced trophoblast cell apoptosis by targeting PARP1 in recurrent spontaneous abortion (RSA). Gynecol Endocrinol 2017;33:274-8. [PMID: 28042738 DOI: 10.1080/09513590.2016.1266476] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
5 Baptista SJ, Silva MM, Moroni E, Meli M, Colombo G, Dinis TC, Salvador JA. Novel PARP-1 Inhibitor Scaffolds Disclosed by a Dynamic Structure-Based Pharmacophore Approach. PLoS One 2017;12:e0170846. [PMID: 28122037 DOI: 10.1371/journal.pone.0170846] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
6 Brady PN, Goel A, Johnson MA. Poly(ADP-Ribose) Polymerases in Host-Pathogen Interactions, Inflammation, and Immunity. Microbiol Mol Biol Rev 2019;83:e00038-18. [PMID: 30567936 DOI: 10.1128/MMBR.00038-18] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
7 Chen X, Mims J, Huang X, Singh N, Motea E, Planchon SM, Beg M, Tsang AW, Porosnicu M, Kemp ML, Boothman DA, Furdui CM. Modulators of Redox Metabolism in Head and Neck Cancer. Antioxid Redox Signal 2018;29:1660-90. [PMID: 29113454 DOI: 10.1089/ars.2017.7423] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
8 Pol JG, Lévesque S, Workenhe ST, Gujar S, Le Boeuf F, Clements DR, Fahrner JE, Fend L, Bell JC, Mossman KL, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. Oncoimmunology 2018;7:e1503032. [PMID: 30524901 DOI: 10.1080/2162402X.2018.1503032] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 11.3] [Reference Citation Analysis]
9 Bilan V, Selevsek N, Kistemaker HAV, Abplanalp J, Feurer R, Filippov DV, Hottiger MO. New Quantitative Mass Spectrometry Approaches Reveal Different ADP-ribosylation Phases Dependent On the Levels of Oxidative Stress. Mol Cell Proteomics 2017;16:949-58. [PMID: 28325851 DOI: 10.1074/mcp.O116.065623] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 5.4] [Reference Citation Analysis]
10 Su S, Lin X, Ding N, Zhang H, Zhang Q, Ding Y, Hou X, Tian Y. Effects of PARP-1 inhibitor and ERK inhibitor on epithelial mesenchymal transitions of the ovarian cancer SKOV3 cells. Pharmacol Rep 2016;68:1225-9. [PMID: 27668317 DOI: 10.1016/j.pharep.2016.08.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
11 Das B, Neilsen BK, Fisher KW, Gehring D, Hu Y, Volle DJ, Kim HS, McCall JL, Kelly DL, MacMillan JB, White MA, Lewis RE. A Functional Signature Ontology (FUSION) screen detects an AMPK inhibitor with selective toxicity toward human colon tumor cells. Sci Rep 2018;8:3770. [PMID: 29491475 DOI: 10.1038/s41598-018-22090-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
12 Li J, Dou D, Li P, Luo W, Lv W, Zhang C, Song X, Yang Y, Zhang Y, Xu Y, Xiao F, Wei Y, Qin J, Li H, Yang X. PARP-1 serves as a novel molecular marker for hepatocellular carcinoma in a Southern Chinese Zhuang population. Tumour Biol 2017;39:1010428317706914. [PMID: 28714367 DOI: 10.1177/1010428317706914] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
13 Huang S, Zhang B, Chen Y, Liu H, Liu Y, Li X, Bao Z, Song Z, Wang Z. Poly(ADP-Ribose) Polymerase Inhibitor PJ34 Attenuated Hepatic Triglyceride Accumulation in Alcoholic Fatty Liver Disease in Mice. J Pharmacol Exp Ther 2018;364:452-61. [PMID: 29317476 DOI: 10.1124/jpet.117.243105] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
14 Umphlett M, Shea S, Tome-Garcia J, Zhang Y, Hormigo A, Fowkes M, Tsankova NM, Yong RL. Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report. BMC Cancer 2020;20:47. [PMID: 31959133 DOI: 10.1186/s12885-020-6540-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
15 Ramsden DB, Waring RH, Barlow DJ, Parsons RB. Nicotinamide N -Methyltransferase in Health and Cancer. Int J�Tryptophan�Res 2017;10:117864691769173. [DOI: 10.1177/1178646917691739] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
16 Manzotti G, Ciarrocchi A, Sancisi V. Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy. Cancers (Basel) 2019;11:E304. [PMID: 30841549 DOI: 10.3390/cancers11030304] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 9.7] [Reference Citation Analysis]
17 Berger NA, Besson VC, Boulares AH, Bürkle A, Chiarugi A, Clark RS, Curtin NJ, Cuzzocrea S, Dawson TM, Dawson VL, Haskó G, Liaudet L, Moroni F, Pacher P, Radermacher P, Salzman AL, Snyder SH, Soriano FG, Strosznajder RP, Sümegi B, Swanson RA, Szabo C. Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. Br J Pharmacol 2018;175:192-222. [PMID: 28213892 DOI: 10.1111/bph.13748] [Cited by in Crossref: 100] [Cited by in F6Publishing: 101] [Article Influence: 20.0] [Reference Citation Analysis]